UC San Diego School of Medicine

Vimentin network dysregulation mediates neurite deficits in SNCA duplication Parkinson’s patient–derived midbrain neurons (2025) Schneider Y, Koller A, Schweigert A, Andert M, Hoffmann L, O’Brien S, Seebauer L, et al. Journal article Immune mechanisms of depression in rheumatoid arthritis (2023) Brock J, Basu N, Schlachetzki JC, Schett G, McInnes IB, Cavanagh J Journal article, Review article Chronic peripheral inflammation: A possible contributor to neurodegenerative diseases (2021) Süß P, Lana AJ, Schlachetzki JC Journal article, Review article Recent smell loss is the best predictor of COVID-19 among individuals with recent respiratory symptoms (2021) Gerkin RC, Ohla K, Veldhuizen MG, Joseph PV, Kelly CE, Bakke AJ, Steele KE, et al. Journal article Author Correction: A monocyte gene expression signature in the early clinical course of Parkinson’s disease (Scientific Reports, (2018), 8, 1, (10757), 10.1038/s41598-018-28986-7) (2020) Schlachetzki J, Prots I, Tao J, Chun HB, Saijo K, Gosselin D, Winner B, et al. Journal article, Erratum More Than Smell-COVID-19 Is Associated With Severe Impairment of Smell, Taste, and Chemesthesis (2020) Parma V, Ohla K, Veldhuizen MG, Niv MY, Kelly CE, Bakke AJ, Cooper KW, et al. Journal article A monocyte gene expression signature in the early clinical course of Parkinson's disease (vol 8, 10757, 2018) (2020) Winner B, Schlachetzki JC, Prots I, Tao J, Chun HB, Saijo K, Gosselin D, et al. Journal article, Erratum Chronic Peripheral Inflammation Causes a Region-Specific Myeloid Response in the Central Nervous System (2020) Süß P, Hoffmann A, Rothe T, Ouyang Z, Baum W, Staszewski O, Schett G, et al. Journal article SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL (2017) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial (2016) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution